Biomarin Pharma opened higher at $58.40, compared with its previous close of $57.49. In the last trading session, the stock traded between $57.86 and $59.37. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Biomarin Pharma is now worth
$ 73.43
resulting in a loss of
$ 26.57 (26.57%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 24 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
+$0.69 (+1.20%)
Day High
$59.37
Day Low
$57.86
Day Open
$58.40
Prev Close
$57.49
Volume
8,88,109
1W Return
2.69%
1M Return
-2.85%
3M Return
-5.18%
6M Return
7.32%
1Y Return
12.18%
Fundamentals
Market Cap ($ Mn)
11,262
PE Ratio
174.69
PB Ratio
1.98
PEG Ratio
4.56
ROE
5.88%
ROCE
6.28%
EPS (TTM)
$0.23
Investment Returns
1 Week
2.69%
1 Month
-2.85%
3 Months
-5.18%
6 Months
7.32%
9 Months
2.09%
Financials
Quarterly
All values in $ Mn
745.1
Mar 25
825.4
Jun 25
776.1
Sep 25
874.6
Dec 25
766.2
Mar 26
989.7
Jun 26
Updates
20Oct
Cantor Fitzgerald reiterates Overweight on BioMarin, holds $86 target
Cantor Fitzgerald reiterated an Overweight rating on BioMarin Pharmaceutical. Analyst Olivia Brayer Saunders maintained the $86 price target. No changes were made to the existing valuation framework.
10 days ago
14Oct
Barclays raises BioMarin price target to $114, maintains Overweight
Barclays raised BioMarin Pharmaceutical's price target to $114 from $111. The firm maintained an Overweight rating on the stock. Analyst Eliana Merle issued the updated recommendation.
BioMarin expects $283 million in pre-tax charges for Q3FY26 due to acquired IPR&D. The company projects a $1.50 unfavorable impact on diluted EPS for Q3FY26. Total pre-tax charges for FY26 are expected to reach $320 million. Full-year diluted EPS impact is estimated at $1.55 unfavorable. Charges include costs associated with the Alesta acquisition.
23 days ago
2Oct
BioMarin presents new efficacy data for Pompe disease therapy
BioMarin presented new efficacy and safety data for POMBILITI and OPFOLDA in late-onset Pompe disease. The presentation occurred at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. No new safety signals were identified in the evaluated combination therapy.
28 days ago
1Oct
BioMarin grants Ascendis license for three growth therapies
BioMarin grants Ascendis Pharma license for Transcon CNP, Navepegritide, and Yuviwel. Ascendis to pay 20% royalty on US sales and 18% on EU, Brazil, and South Korea sales. Royalty payments continue until May 2030. All pending litigation between the two companies is dismissed.
29 days ago
14Sep
BioMarin appoints BMS Chief Research Officer Robert Plenge to board
BioMarin appoints Robert Plenge to its Board of Directors effective September 10, 2026. Plenge serves as Chief Research Officer and Head of Research at Bristol Myers Squibb. CEO Alexander Hardy cites Plenge's expertise in human genetics and drug discovery. Plenge previously held senior roles at Celgene Corp. and Merck & Co.
